Lineage Cell Therapeutics Overview

Lineage Cell Therapeutics Other Income Expense Net

Other Income/Expense Net for LCTX.

Quarterly Other Income/Expense

$2.80M

↑ 18.51% YoY

As of Mar 31, 2026

Annual Other Income/Expense (TTM)

-$31.61M

↓ 712.81% YoY

Trailing 12 months ending Mar 31, 2026

Average Other Income/Expense (Comparison Companies)

Other Income Expense Net History

Other Income Expense Net Comparison

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin